Search results
Showing 151 to 165 of 887 results for score
Evidence-based recommendations on Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C.
Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)
Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making
Arthroscopic trochleoplasty for patellar instability (HTG328)
Evidence-based recommendations on arthroscopic trochleoplasty for patellar instability. This involves reshaping the bony anatomy of the trochlea by deepening the groove or elevating the lateral wall.
Cardiovascular disease prevention: risk assessment (modifiable risk factors) (IND270)
This indicator covers the percentage of people aged 43 to 84 years with a modifiable risk factor who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Evidence-based recommendations on soft-palate implants for obstructive sleep apnoea. This involves inserting implants into the soft palate of the mouth to stiffen it over subsequent weeks and make it less likely to vibrate.
View recommendations for HTG155Show all sections
Sections for HTG155
This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.
Evidence-based recommendations on 12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT; Acarizax) for treating allergic rhinitis and allergic asthma caused by house dust mites.
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)
Evidence-based recommendations on vedolizumab (Entyvio) for previously treated moderately to severely active Crohn’s disease in adults.
This guideline covers identifying, assessing and managing alcohol-use disorders (harmful drinking and alcohol dependence) in adults and young people aged 10 to 17 years. It aims to reduce harms (such as liver disease, heart problems, depression and anxiety) from alcohol by improving assessment and setting goals for reducing alcohol consumption.
Insertion of an annular disc implant at lumbar discectomy (HTG358)
Evidence-based recommendations on insertion of an annular disc implant at lumbar discectomy. This involves inserting an implant to close the hole that is left in a torn disc after any bulging material has been removed during surgery.
View recommendations for HTG358Show all sections
Placement of pectus bar for pectus excavatum (also known as MIRPE or the Nuss procedure) (HTG199)
Evidence-based recommendations on placement of pectus bar for pectus excavatum (Nuss procedure). This involves placing one or two steel (pectus) bars under the breastbone with the aim of raising it and correcting the abnormal shape.
View recommendations for HTG199Show all sections
Sections for HTG199
Partial replacement of the meniscus of the knee using a biodegradable scaffold (HTG289)
Evidence-based recommendations on partial replacement of the meniscus of the knee using a biodegradable scaffold. This involves placing a biodegradable implant into the meniscus to support regrowth and repair of the damage.
View recommendations for HTG289Show all sections
Sections for HTG289
Evidence-based recommendations on insertion of a double balloon catheter for induction of labour in pregnant women without previous caesarean section. The catheter aims to help induction by causing dilation of the cervix when the cervix is unfavourable for induction. The double balloon squeezes the cervix and stimulates local prostaglandin release, which leads to cervical ripening.
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)
Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.